Curcuminoids and alpha-tocopherol

PreclinicalSmall molecule

Curcuminoids and alpha-tocopherol is one of 18 small molecule programs targeting Beta-Thalassemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Beta-ThalassemiaActive, not recruiting

Beta-ThalassemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Beta-Thalassemia

#DrugCompanyPhaseTrials

Exjade

Novartis

Approved

5 2

Thalomid

Bristol-Myers Squibb

Approved

3 3

Droxia

TTheravia

Approved

4 4

Desferal

Glucophage

2 6

Viagra

VViatris Specialty LLC

Approved

1 7

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—8

Ferriprox

Chiesi Farmaceutici S.p.A.

Approved

—9

CTX001

Vertex Pharmaceuticals

Phase 3

2 10

ACE-536

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Beta-Thalassemia1 trial

Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients

Completed·MMahidol University·N/A·NCT01597765·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Curcuminoids and alpha-tocopherol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Curcuminoids and alpha-tocopherol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Curcuminoids and alpha-tocopherol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mahidol University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMahidol University

Curcuminoids and alpha-tocopherol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Beta-Thalassemia1 trial

References

Drug Info

Quick Facts

Related News